Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

被引：0

作者：

Witzig, Thomas E. ^{[1
]}

Vose, Julie M. ^{[2
]}

Zinzani, Pier Luigi ^{[3
]}

Reeder, Craig B. ^{[4
]}

Buckstein, Rena ^{[5
]}

Polikoff, Jonathan ^{[6
]}

Guo, Pingshan ^{[7
]}

Pietronigro, Dennis ^{[7
]}

Ervin-Haynes, Annette ^{[7
]}

Czuczman, Myron S. ^{[8
]}

机构：

[1] Mayo Clin, Coll Med, Rochester, MN USA

[2] Univ Nebraska Med Ctr, Internal Med Sect Hematol Oncol, Omaha, NE USA

[3] Univ Bologna, Dept Hematol Oncol, Inst Hematol L&A Seragnoli, Bologna, Italy

[4] Mayo Clin, Scottsdale, AZ USA

[5] Sunnybrook Odette Canc Ctr, Dept Hematol Oncol, Toronto, ON, Canada

[6] Kaiser Permanente Med Grp, San Diego, CA USA

[7] Celgene Corp, Summit, NJ USA

[8] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：668 / 669

页数：2